A Phase 4 interventional study of Furosemide intravenous solution and Furosemide intravenous solution in Heart Failure, Heart Failure - NYHA II - IV and Heart Failure Acute, sponsored by Lakeland Regional Health Systems, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-09.
Sponsored by Lakeland Regional Health Systems, Inc. · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing furosemide in Heart Failure — 5 open to participants now, 5 under way, 1 of them phase 3. Furosemide · Heart Failure.
Among the 36 studies testing furosemide in Heart Failure, this one is the 3rd largest by planned enrollment of the 35 interventional ones that give a count, is the only one that started in 2026, is one of 17 in phase 4, and was the 36th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →5 of the 36 studies testing furosemide in Heart Failure are open now, in 2 countries. Recruiting first, the newest first:
University of Florida · Sites in United States
Ages 18–80
Copenhagen University Hospital, Rigshospitalet · Sites in Denmark
Ages 18+
Heart Center Research, LLC · Sites in United States
Ages 19+
University of Texas Southwestern Medical Center · Sites in United States
Ages 18–100
By country, each count listing its studies:
Furosemide: first FDA approval 1966 (LASIX), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 7 · Phase 4 17
First in 2000; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 600 is above the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 42 across the 35 interventional studies. Of the 23 that completed or were terminated, 9 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 36 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Lakeland Regional Health Systems, Inc. as lead sponsor.
Lakeland Regional Health Systems, Inc. has 1 study filed under Heart Failure — fewer than ten, so there is no comparison to draw.
3 of the studies testing furosemide in Heart Failure that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06979726University of FloridaGator SCALES-WHF: SubCutaneous Administration of Lasix to Eliminate Symptoms of Worsening Heart Failure | 2026-11-30 |
| NCT05276219Copenhagen University Hospital, RigshospitaletDECONGEST-AHF: Vasodilatation or Loop Diuretics in Acute Heart Failure | 2027-05-01 |
| NCT07263035Lakeland Regional Health Systems, Inc.Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure | 2027-06-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 36 studies testing furosemide in Heart Failure, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if increasing the dose of diuretics to achieve a higher urine sodium target produces better clinical results when treating patients hospitalized with acute heart failure when compared to lower urine sodium target and standard of care.
The main questions it aims to answer are:
Researchers will compare natriuresis-guided arms with standard of care to see if targeting higher natriuresis goals improves significantly over current practice.
Participants will submit urine samples at routine intervals after being given diuretics to evaluate urine sodium concentration. If urine sodium is low then diuretic dose will be increased.
Patients will be randomized into one of three groups: 50 micromolar natriuresis, 85 micromolar natriuresis, and standard of care. The natriuresis arms will have urine sodium assessed two to four hours administration of intravenous diuretics. If the natriuretic response is inadequate they will immediately receive a higher dose of diuretic. This process will be repeated for the first 72 hours of admission.
Inclusion Criteria:
The study will target adults 18 years of age or older admitted to Lakeland Regional Medical Center who:
Have at least one of the following signs of hypervolemia:
Exclusion Criteria:
Exclusion criteria include:
Traditional diuretic dosing adjustment per provider
Drug: Furosemide intravenous solution
Diuretics will be titrated to achieve a urine sodium concentration of 50 mmol/L
Drug: Furosemide intravenous solution
Diuretics will be titrated to achieve a urine sodium concentration of 85 mmol/L
Drug: Furosemide intravenous solution
Diuretics will be titrated to achieve a urine sodium concentration of 50 mmol/L
Also known as: Lasix
Diuretics will be titrated to achieve a urine sodium concentration of 85 mmol/L
Also known as: Lasix
Standard of care
Also known as: Lasix
Natriuresis at 24 hours
24-hour natriuresis as measured by urine sodium in a 24-hour urine collection
Time frame: 24 hours
Natriuresis at 48 hours
Total urine sodium assessed by 24-hour urine collection
Time frame: 48 hours after enrollment in trial
Diuresis at 24 hours
Total urine volume assessed by 24 hour collection
Time frame: 24 hours after enrollment
Diuresis at 48 hours
Total urine volume assessed via 24-hour collection
Time frame: 48 hours after enrollment
Length of Stay
Duration of hospitalization
Time frame: From the date and time of admission order until the date and time of discharge order, assessed for each participant up to 30 days after admission or death from any cause, whichever comes first.
Readmission of any cause at 30 days
Proportion of participants who experience an unplanned hospital readmission for any cause within 30 days after the index hospital discharge.
Time frame: 30 days after discharge
Readmission rate of any cause at 90 days
Proportion of participants who experience an unplanned hospital readmission for any cause within 90 days after the index hospital discharge.
Time frame: 90 days after the time of discharge
Readmission rate of Heart failure
Proportion of participants who experience an unplanned hospital readmission specifically for heart failure within 30 days after the index hospital discharge.
Time frame: 30 days
Readmission rate for heart failure
Proportion of participants who experience an unplanned hospital readmission specifically for heart failure within 90 days after the index hospital discharge.
Time frame: 90 days
Weight change
Difference in weight from admission compared to discharge
Time frame: Weight assessed at baseline within 24 hours of hospital admission and at discharge, with the discharge weight measured on the discharge day up to 30 days after admission.
Net fluid balance
Cumulative difference between total fluid intake and output during the hospitalization
Time frame: Net fluid balance assessed from baseline Day 1 of admission through hospital discharge, with discharge assessment on the discharge day up to 30 days after admission.
Plan to share: Undecided — Yes
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Jun 2027, 14 months after the start.
Of 165 non-industry phase 4 interventional studies under Heart Failure, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 56. This study's planned 14 months is below that.
Counting every sponsor, half of 184 studies reached it within 31 months; a quarter within 21 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Furosemide